AU2010261540B2 - Crystalline form of pemirolast - Google Patents

Crystalline form of pemirolast Download PDF

Info

Publication number
AU2010261540B2
AU2010261540B2 AU2010261540A AU2010261540A AU2010261540B2 AU 2010261540 B2 AU2010261540 B2 AU 2010261540B2 AU 2010261540 A AU2010261540 A AU 2010261540A AU 2010261540 A AU2010261540 A AU 2010261540A AU 2010261540 B2 AU2010261540 B2 AU 2010261540B2
Authority
AU
Australia
Prior art keywords
compound
pemirolast
sodium
treatment
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010261540A
Other languages
English (en)
Other versions
AU2010261540A2 (en
AU2010261540A1 (en
Inventor
Karol Horvath
Anett Perlberg
Ulrika Rosenstrom
Martin Viertelhaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardoz AB
Original Assignee
Cardoz AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz AB filed Critical Cardoz AB
Publication of AU2010261540A2 publication Critical patent/AU2010261540A2/en
Publication of AU2010261540A1 publication Critical patent/AU2010261540A1/en
Application granted granted Critical
Publication of AU2010261540B2 publication Critical patent/AU2010261540B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
  • Dental Preparations (AREA)
AU2010261540A 2009-06-16 2010-06-15 Crystalline form of pemirolast Ceased AU2010261540B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18734809P 2009-06-16 2009-06-16
US18735509P 2009-06-16 2009-06-16
US61/187,348 2009-06-16
US61/187,355 2009-06-16
PCT/GB2010/001168 WO2010146348A2 (en) 2009-06-16 2010-06-15 New crystalline form of pemirolast

Publications (3)

Publication Number Publication Date
AU2010261540A2 AU2010261540A2 (en) 2012-01-19
AU2010261540A1 AU2010261540A1 (en) 2012-01-19
AU2010261540B2 true AU2010261540B2 (en) 2016-04-14

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010261540A Ceased AU2010261540B2 (en) 2009-06-16 2010-06-15 Crystalline form of pemirolast

Country Status (31)

Country Link
US (3) US20120157415A1 (cg-RX-API-DMAC10.html)
EP (2) EP2443120B1 (cg-RX-API-DMAC10.html)
JP (2) JP5722317B2 (cg-RX-API-DMAC10.html)
KR (2) KR20170049645A (cg-RX-API-DMAC10.html)
CN (1) CN102596202B (cg-RX-API-DMAC10.html)
AR (1) AR077915A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010261540B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1015559A2 (cg-RX-API-DMAC10.html)
CA (1) CA2765408A1 (cg-RX-API-DMAC10.html)
CY (1) CY1118413T1 (cg-RX-API-DMAC10.html)
DK (1) DK2443120T3 (cg-RX-API-DMAC10.html)
EA (1) EA025865B1 (cg-RX-API-DMAC10.html)
ES (1) ES2613059T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20170023T1 (cg-RX-API-DMAC10.html)
HU (1) HUE032978T2 (cg-RX-API-DMAC10.html)
IL (1) IL216670A (cg-RX-API-DMAC10.html)
LT (1) LT2443120T (cg-RX-API-DMAC10.html)
ME (1) ME02685B (cg-RX-API-DMAC10.html)
MX (1) MX2011013676A (cg-RX-API-DMAC10.html)
NZ (1) NZ596747A (cg-RX-API-DMAC10.html)
PL (1) PL2443120T3 (cg-RX-API-DMAC10.html)
PT (1) PT2443120T (cg-RX-API-DMAC10.html)
RS (1) RS55558B1 (cg-RX-API-DMAC10.html)
SA (1) SA114350792B1 (cg-RX-API-DMAC10.html)
SG (1) SG176295A1 (cg-RX-API-DMAC10.html)
SI (1) SI2443120T1 (cg-RX-API-DMAC10.html)
SM (2) SMT201700085T1 (cg-RX-API-DMAC10.html)
TW (1) TWI504599B (cg-RX-API-DMAC10.html)
UY (1) UY32711A (cg-RX-API-DMAC10.html)
WO (2) WO2010146348A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201109045B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780382A1 (en) * 2009-11-13 2011-05-19 Cardoz Ab Pemirolast for the treatment of systemic low grade inflammation
EP3978002A1 (en) * 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
AU2017340594B2 (en) * 2016-10-03 2020-09-10 Brivention Pharmaceutical (Shanghai) Inc. Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド［１，２―ａ］ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
BRPI0615775B1 (pt) 2005-09-16 2021-08-10 Daiichi Sankyo Company, Limited Processos para a produção de compostos derivados de diamida oticamente ativos
EA200900815A1 (ru) * 2006-12-18 2009-12-30 Кардос Аб Новая комбинация, предназначенная для лечения воспалительных нарушений
US20100168137A1 (en) * 2006-12-20 2010-07-01 Johan Raud Combination for use in the treatment of inflammatory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Also Published As

Publication number Publication date
WO2010146341A2 (en) 2010-12-23
WO2010146348A2 (en) 2010-12-23
IL216670A0 (en) 2012-02-29
CN102596202A (zh) 2012-07-18
SA114350792B1 (ar) 2015-11-10
WO2010146348A9 (en) 2012-05-03
EA025865B1 (ru) 2017-02-28
ZA201109045B (en) 2013-05-29
WO2010146341A3 (en) 2011-03-03
US20120157415A1 (en) 2012-06-21
JP5722317B2 (ja) 2015-05-20
KR20170049645A (ko) 2017-05-10
TWI504599B (zh) 2015-10-21
JP2015120750A (ja) 2015-07-02
EP2443120B1 (en) 2016-11-02
DK2443120T3 (en) 2017-01-09
JP2012530118A (ja) 2012-11-29
LT2443120T (lt) 2017-02-10
SG176295A1 (en) 2012-01-30
HRP20170023T1 (hr) 2017-03-10
WO2010146348A3 (en) 2011-03-03
SI2443120T1 (sl) 2017-04-26
SMT201700085T1 (it) 2017-03-08
US20140329839A1 (en) 2014-11-06
NZ596747A (en) 2014-01-31
AU2010261540A2 (en) 2012-01-19
AR077915A1 (es) 2011-10-05
IL216670A (en) 2017-02-28
PT2443120T (pt) 2017-02-08
BRPI1015559A2 (pt) 2016-04-26
HUE032978T2 (hu) 2017-11-28
CN102596202B (zh) 2015-01-21
RS55558B1 (sr) 2017-05-31
TW201100422A (en) 2011-01-01
US20170202839A1 (en) 2017-07-20
CA2765408A1 (en) 2010-12-23
UY32711A (es) 2011-01-31
AU2010261540A1 (en) 2012-01-19
ME02685B (me) 2017-06-20
EP2443120A2 (en) 2012-04-25
KR20120032530A (ko) 2012-04-05
CY1118413T1 (el) 2017-06-28
EA201200017A1 (ru) 2013-10-30
US9006431B2 (en) 2015-04-14
PL2443120T3 (pl) 2017-04-28
SMT201700085B (it) 2017-03-08
ES2613059T3 (es) 2017-05-22
MX2011013676A (es) 2012-02-08
EP3141549A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
US20170202839A1 (en) Crystalline Form of Pemirolast
KR101549318B1 (ko) 안지오텐신 수용체 길항제 및 ｎｅｐ 억제제의 제약 조합물
TWI876902B (zh) 經四氫哌喃(thp)取代之雙環嘧啶二酮化合物
TW200300081A (en) Pde9 inhibitors for treating cardiovascular disorders
CN105503760A (zh) 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
US20160250217A1 (en) Crystalline form of pemirolast
HK1238628A1 (en) Crystalline form of pemirolast for use in the treatment of inflammations
HK1169385A (en) Crystalline form of pemirolast
HK1169385B (en) Crystalline form of pemirolast
TW201028390A (en) Flavononol renin inhibitor compounds and methods of use thereof
AU2010317712A1 (en) Pemirolast for the treatment of systemic low grade inflammation
TW201113019A (en) Therapeutic drug for hypertension or prehypertension
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
RU2459809C2 (ru) Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2023208103A1 (zh) 可用于痛风的化合物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 DEC 2011

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired